{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-26-003397","form_type":"8-K","ticker":"CRVS","cik":"0001626971","company_name":"Corvus Pharmaceuticals, Inc.","filed_at":"2026-05-14T11:01:18+00:00","discovered_at":"2026-05-14T11:05:00.347530+00:00","generated_at":"2026-05-14T11:08:30.945297+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Corvus reports positive Phase 1 soquelitinib data in atopic dermatitis; durable remissions without rebound","bullets":["72-patient Phase 1 trial met safety and efficacy endpoints; no severe adverse events.","Cohort 4 (200 mg BID for 56 days): 75% achieved EASI 75, 25% achieved EASI 90, 33% IGA 0/1.","Biomarker data confirms ITK inhibition reduces Th2/Th17 cytokines and increases persistent Tregs.","Drug-free remission maintained in post-treatment follow-up (up to 90 days) with no disease rebound.","SIERRA1 Phase 2 trial for moderate-to-severe atopic dermatitis now enrolling ~200 patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-003397","json":"https://secwatch.observer/filing/0001171843-26-003397.json","markdown":"https://secwatch.observer/filing/0001171843-26-003397.md","text":"https://secwatch.observer/filing/0001171843-26-003397.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1626971/000117184326003397/0001171843-26-003397-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1626971/000117184326003397/f8k_051426.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T11:08:30.945297+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}